Promising antibody combo aims to stop bone cancer relapse in kids and young adults

NCT ID NCT02502786

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 18 times

Summary

This study tests whether a lab-made antibody (Hu3F8) plus a drug called GM-CSF can help keep osteosarcoma, a type of bone cancer, from returning after it has already come back once. About 46 children and young adults (ages 1 to 40) whose cancer is in a second remission will receive the treatment. The goal is to see if this approach extends the time before the cancer returns or prevents relapse altogether.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Children's Hospital of Los Angeles (Data Collection Only)

Los Angeles, California, 90027, United States
MD ANDERSON CANCER CENTER (Data Collection Only)

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.

RECURRENT OSTEOSARCOMA